Results for this period
Full year1 April 2025–31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The company recorded research and development expenses of ¥803 million and selling, general and administrative expenses of ¥406 million. Non-operating income included grant income of ¥57 million and other items, while non-operating expenses included stock issuance expenses of ¥13 million and other items. Extraordinary losses included an impairment loss of ¥5 million.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥3 million (YoY +42.4%) |
| Operating profit | ¥-1,207 million |
| Ordinary income | ¥-1,138 million |
| Profit attributable to owners of the parent | ¥-1,145 million |
| Net income per share | ¥(23.07) |
| Equity ratio | End of the current fiscal period 95.4 / End of previous period 95.5 |
| Total assets | ¥2,976 million |
| Net assets | ¥2,841 million |
| Cash flows from operating activities | ¥-1,110 million |
| Cash flows from investing activities | ¥289 million |
| Cash flows from financing activities | ¥911 million |
| Cash and cash equivalents at end of period | ¥1,927 million |
| Full-year earnings forecast | Net Sales ¥17 million (YoY +496.7%) / Operating profit ¥-1,547 million / Ordinary income ¥-1,542 million / Net income ¥-1,543 million |
| Annual Dividend Forecast | 0 yen and sen → 0 yen and sen |
| Depreciation and amortization | ¥3,995 thousand |
| Impairment loss | ¥5,578 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Impairment Losses ¥5,578 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | Between 1 April and 13 May 2026, 14,400 of the 19th series of stock acquisition rights were exercised, and 1,440,000 common shares were issued. Total proceeds from the exercise were ¥121,440 thousand, while capital and capital reserves each increased by ¥60,741 thousand. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 54,332,640 |
| Treasury Shares at Period-End | 23,824 |
| Factors Behind Changes in Business Performance | The company recorded research and development expenses of ¥803 million and selling, general and administrative expenses of ¥406 million. Non-operating income included grant income of ¥57 million and other items, while non-operating expenses included stock issuance expenses of ¥13 million and other items. Extraordinary losses included an impairment loss of ¥5 million. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company reported an operating loss due to research and development expenses of ¥803 million and selling, general and administrative expenses of ¥406 million. For the ordinary loss, the company recorded grant income of ¥57 million and other items, while also recording stock issuance expenses of ¥13 million and other items. For the net loss, the company recorded an impairment loss of ¥5 million on fixed assets.